Merck & Co. Inc. (MRK)

80.84
NYSE : Health Technology
Prev Close 79.56
Day Low/High 78.83 / 80.86
52 Wk Low/High 65.25 / 92.64
Avg Volume 13.08M
Exchange NYSE
Shares Outstanding 2.52B
Market Cap 200.82B
EPS 3.80
P/E Ratio 19.99
Div & Yield 2.44 (2.87%)
Black History Month on Wall Street

Black History Month on Wall Street

This Black History month, we are taking a look at the African Americans who have made it to the C-Suite and are making a difference. And sadly, there are not many. Watch our video to learn the names you should know now.

Intermediate Trade: Merck

Intermediate Trade: Merck

I prefer a bullishly biased call spread on Merck.

Ignore the Gaps and Merck Is Ready for Further Strong Gains

Ignore the Gaps and Merck Is Ready for Further Strong Gains

It's time again to visit with the latest charts and indicators.

Jim Cramer: I Blame the Pajama Traders for This Selloff

Jim Cramer: I Blame the Pajama Traders for This Selloff

They make more irrational, stupid moves based on nothing than I ever thought possible.

Cramer: 5 Rules for Our Beast of a Bull Market

Cramer: 5 Rules for Our Beast of a Bull Market

It might look easy now, but it looked easy in 1999, too.

Video: Jim Cramer on Dow 26,000, Merck, BlackRock and Goldman Sachs

Video: Jim Cramer on Dow 26,000, Merck, BlackRock and Goldman Sachs

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Tuesday's trending topics.

Intermediate Trade: Merck

Intermediate Trade: Merck

Consider that MRK analysts are projecting earnings growth this year and next.

Cramer: There Are the Dogs of the Dow and Then There's GE

Cramer: There Are the Dogs of the Dow and Then There's GE

A rundown of the five worst performing stocks in the Dow Industrials.

Intermediate Trade: Merck

Intermediate Trade: Merck

The trade is the out-of-the-money vertical call spread expiring in March.

Jim Cramer: Breakouts Are the New Normal for This Stock Market

Jim Cramer: Breakouts Are the New Normal for This Stock Market

We have seen this pattern many times in the last few months, and it is a surreal pattern for traders.

Novice Trade: Pfizer

Novice Trade: Pfizer

The trade for highly discretionary capital is the in-the-money, long call shooter expiring in January.

Some Afternoon Observations

* Thus far, my expectation of an "inside day" has been accurate. SPDR S&P 500 ETF  has traded in a fifty cent range most of the day. * Bonds are at the day's highs. +$0.88. Yield on the 10-year U.S. note is down by 3.5 basis points to 2.32% (where y...

Hot Trade: Merck

Hot Trade: Merck

I prefer a bullish put spread expiring in June.

Wall Street at Records as GOP Tax Bill Heads to Senate Vote

Wall Street at Records as GOP Tax Bill Heads to Senate Vote

Wall Street ended at records as the Senate GOP's tax bill cleared the Senate Budget Committee, moving it toward the floor for a vote later this week.

Interesting Statistics

Some interesting statistics on the day: * Bitcoin is trading at $8.240, for a gain of nearly three percent today.  * CNN's Fear and Greed Indicator stands at a neutral 49.  * Gold is -$17.70, a drop of -1.4%. * Lumber is -$10, a -2.3% decline. * 3M ...

Here's What's Up This A.M.

The Nasdaq (QQQs) turn slightly negative as most of the FANGs reverse lower.   Retail, generics (Teva and Mylan ), big pharma (Merck and Bristol-Myers Squibb ) and biotech (Allergan , Gilead Sciences , Celgene ) are conspicuous to the downside.   Co...

5 Small Biotechs Receive Shots in the Arm

5 Small Biotechs Receive Shots in the Arm

Favorable quarterly results and FDA drug approvals should help lift these five names.

5 Small Biotechs Receive Shots in the Arm

5 Small Biotechs Receive Shots in the Arm

Favorable quarterly results and FDA drug approvals should help lift these five names.

Notable Movements

In terms of sector price movement today: * FANGs continue to extend recent gains.  * Retail has picked up a bid late in the day. Walmart Dillard's and Foot Locker are upside features. * Big Pharma stronger -- led by Merck ,Bristol-Myers Squibb , Lil...

Acadia, Dynavax Make the Biotech Mailbag

Acadia, Dynavax Make the Biotech Mailbag

Readers have asked about Acadia Pharmaceuticals and Dynavax Technologies, so we answer.

Individual Stocks Have Been All Over the Map While Indexes Doze

Individual Stocks Have Been All Over the Map While Indexes Doze

It's all about dislocation, dislocation, dislocation.

Merck & Co Raised to Hold at Jefferies

Closing Bell: LIVE MARKETS BLOG

Closing Bell: LIVE MARKETS BLOG

It was a down day across the board on Wall Street.

Cramer: We're Seeing the Best of Times and the Worst of Times at the Same Time

Cramer: We're Seeing the Best of Times and the Worst of Times at the Same Time

It depends on which aisle of the stock market you're on.

Which Way Are These Stocks Going?

Which Way Are These Stocks Going?

Finding bullish and bearish reversals in the market.

Merck's Price Strength Is Ailing

Merck's Price Strength Is Ailing

Even if the stock bounces, an advance is unlikely.

Midday Update: Stocks Mixed as Healthcare Struggles, Tech Continues Gains

Midday Update: Stocks Mixed as Healthcare Struggles, Tech Continues Gains

Stocks were mixed at midday Monday as Merck weighed on the Dow and tech strength boosted the Nasdaq.

3 Small-Caps on My Growth Stock Radar

3 Small-Caps on My Growth Stock Radar

LGI Homes, ANI Pharmaceuticals and Sonus Networks are worth considering.

Stop Worrying About Valuations After Amazon, Alphabet and Microsoft's Earnings

Stop Worrying About Valuations After Amazon, Alphabet and Microsoft's Earnings

The revenue and profit gains from some of the biggest technology companies like Amazon AMZN, Alphabet GOOGL and Microsoft MSFT show that valuations aren't so stretched.

There Is Sound Fundamental Reasoning Behind the Positivity: Market Recon

There Is Sound Fundamental Reasoning Behind the Positivity: Market Recon

The ECB's super dovish message was good for the markets.